Clinical trials: Treatment Resistant Disorders, open to volunteers
Epilepsy, Temporal Lobe, Drug Resistant Epilepsy
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using…
- Trial name
- NCT05947656
- Testing
- NaviFUS System
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Genovate-NaviFUS (Australia) Pty Ltd.
COPD
Refractory Breathlessness in COPD
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA)…
- Trial name
- RB-COPD (NCT07160322)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Seoul National University
Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute
Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children.
- Conditions
- Methicillin Resistant Staphylococcus Aureus, Osteomyelitis Acute, Septic Arthritis, Orbital Cellulitis
- Trial name
- NCT06982105
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Indiana University
Type 1 Diabetes, Closed Loop
Semi-closed Loop Automated Insulin Therapy in the Pediatric Population Aged 2-6 Years With Type 1 Diabetes: Impact on Quality of Life and Glycemic Control
The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today. The treatment for type 1 diabetes is insulin therapy.
- Conditions
- Type 1 Diabetes, Closed Loop, Insulin, Quality of Life
- Trial name
- Diablife (NCT06875167)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Fondation Lenval
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Resistance-Optimised Antimicrobial Dosing in Critically Ill Patients, a Randomised Controlled Trial
Critically ill people who need a breathing machine often develop hospital-acquired lung infections. These infections are commonly treated with the antibiotics piperacillin/tazobactam or meropenem.
- Conditions
- Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP), Nosocomial Respiratory Infection, Critical Illness
- Trial name
- ROAD-RCT (NCT07820501)
- Testing
- Resistance-Optimised Precision Dosing, Standard Care Dosing
- Volunteers
- 610 people
- Sponsor
- The University of Queensland
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
- Trial name
- NCT06983756
- Testing
- Erythropoietin
- Volunteers
- 66 people
- Sponsor
- Fayoum University
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer
This study is a Prospective, Single-arm, Phase II clinical trial. The purpose of this study is to find out if taking Etoposide Capsules combined With Bevacizumab and Iparomlimab and Tuvonralimab is safe and works well for people…
- Conditions
- Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa)
- Trial name
- NCT07117877
- Testing
- Etoposide Capsules, Bevacizumab, Iparomlimab and Tuvonralimab (QL1706)
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Fudan University
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Intravenous Ketamine for Treatment-Resistant Depression
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA…
- Trial name
- G2K (NCT06668571)
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Bladder, Lower Urinary Track Symptoms
Low-Energy Shock Wave Therapy for Overactive Bladder in Women With Metabolic Syndrome
Overactive bladder (OAB) is a common condition that causes urinary urgency, frequent urination, and nocturia, which can significantly affect quality of life.
- Conditions
- Bladder, Lower Urinary Track Symptoms, Metabolic Syndrome, Urgency-Frequency
- Trial name
- NCT07563764
- Testing
- Low-Energy Extracorporeal Shock Wave Therapy (LiESWT)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- KMUHIRB-F(I)-20230051
Non-small-cell Lung Cancer
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Objective to compare the efficacy and safety of TQB2450 injection combined with anlotinib and chemotherapy, and TQB2450 injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer subjects who…
- Trial name
- NCT06141226
- Testing
- TQB2450 +Anlotinib+Docetaxel
- Where
- 5 sites in China
- Volunteers
- 148 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lymphoma Cancer
Virus-associated Tumour Microenvironment: Characterisation and Immunological Mechanisms of Resistance to Anti-tumour Treatments
The presence or absence of viruses affects the characteristics of cancer, the response to anti-cancer treatments, and the prognosis of the disease.
- Trial name
- VIRONMENT 2 (NCT07028866)
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with…
- Trial name
- NCT06466122
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kerry Rogers
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
This study aims to evaluate the safety and effectiveness of an experimental biological dressing called TrophiPatch, applied to adults with chronic leg ulcers of diabetic or vascular orign.
- Trial name
- RESCUE-PATCH (NCT07048054)
- Testing
- TrophiPatch: allogeneic adipose-derived stromal cell patch
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Nicolò Brembilla
Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent).
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT05231122
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Roswell Park Cancer Institute
Depressive Disorder, Treatment-Resistant
rTMS With and Without Text4Support for the Treatment of Resistant Depression.
This study is a multicenter prospective, parallel design, two-arm, rater-blinded randomized controlled pilot trial. Participants will be randomly assigned to one of two treatment conditions.
- Trial name
- NCT05570344
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS), Repetitive Transcranial Magnetic Stimulation (rTMS) Plus Text4Support
- Where
- 2 sites in Canada
- Volunteers
- 200 people
- Sponsor
- University of Alberta
Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus
Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes
The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery.
- Conditions
- Type 1 Diabetes (T1D), Glycemic Control for Diabetes Mellitus, Insulin, Ketones
- Trial name
- WBH003 (NCT07186660)
- Testing
- CIR-0602K
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia